Merck & Co Target of Unusually High Options Trading (MRK)
Merck & Co (NYSE:MRK) was the recipient of some unusual options trading on Wednesday. Stock investors purchased 14,888 put options on the stock, Stock Ratings Network reports. This represents an increase of approximately 159% compared to the average daily volume of 5,739 put options.
A number of analysts have recently weighed in on MRK shares. Analysts at BMO Capital Markets raised their EPS on shares of Merck & Co (NYSE:MRK) in a research note to investors on Tuesday. They now have a “market perform” rating and a $50.00 price target on the stock. Separately, analysts at TheStreet reiterated a “buy” rating on shares of Merck & Co (NYSE:MRK) in a research note to investors on Tuesday, September 3rd. Finally, analysts at TheStreet reiterated a “buy” rating on shares of Merck & Co (NYSE:MRK) in a research note to investors on Friday, August 23rd.
Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have issued a buy rating to the company. Merck & Co has an average rating of “Hold” and a consensus price target of $50.96.
Shares of Merck & Co (NYSE:MRK) opened at 48.14 on Thursday. Merck & Co has a 1-year low of $40.02 and a 1-year high of $50.16. The stock has a 50-day moving average of $47.93 and a 200-day moving average of $46.63. The company has a market cap of $140.9 billion and a P/E ratio of 28.57.
Merck & Co (NYSE:MRK) last posted its quarterly earnings results on Tuesday, July 30th. The company reported $0.84 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.82 by $0.02. The company had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $11.22 billion. During the same quarter last year, the company posted $1.05 earnings per share. Merck & Co’s revenue was down 10.6% compared to the same quarter last year. On average, analysts predict that Merck & Co will post $3.48 earnings per share for the current fiscal year.
Merck & Co, Inc (NYSE:MRK) is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.